ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Connecticut » Pulmonary Disease

Top Pulmonary Disease Prescribers in Connecticut

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
CHIRSTOPHER MANFREDI DO

Pulmonary Disease

835

$162K

118
104 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

76%
prescriptions for brand name drugs

Avg: 64%

$194
Average prescription price

Avg: $170

LORRAINE TROW M.D.

Pulmonary Disease

835

$112K

180
149 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

47%
prescriptions for brand name drugs

Avg: 64%

$134
Average prescription price

Avg: $170

JOHN DAY MD

Pulmonary Disease

832

$178K

127
106 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 64%

$214
Average prescription price

Avg: $170

BRETT VOLPE MD

Pulmonary Disease

794

$106K

99
65 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

47%
prescriptions for brand name drugs

Avg: 64%

$133
Average prescription price

Avg: $170

JAMES KRINSLEY M.D.

Pulmonary Disease

777

$151K

119
104 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

74%
prescriptions for brand name drugs

Avg: 64%

$194
Average prescription price

Avg: $170

THOMAS BOTTA M.D.

Pulmonary Disease

752

$141K

194
153 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 64%

$187
Average prescription price

Avg: $170

KENNETH DOBULER M.D.

Pulmonary Disease

750

$151K

123
101 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

77%
prescriptions for brand name drugs

Avg: 64%

$201
Average prescription price

Avg: $170

MARLENE SCHWARTZ M.D.

Pulmonary Disease

722

$153K

120
101 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

84%
prescriptions for brand name drugs

Avg: 64%

$212
Average prescription price

Avg: $170

TERENCE TROW MD

Pulmonary Disease

722

$2.21M

47
24 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

83%
prescriptions for brand name drugs

Avg: 64%

$3066
Average prescription price

Avg: $170

MARGARET WOZNICA MD

Pulmonary Disease

695

$156K

80
72 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

75%
prescriptions for brand name drugs

Avg: 64%

$225
Average prescription price

Avg: $170

TODD BISHOP DO

Pulmonary Disease

694

$151K

135
109 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

78%
prescriptions for brand name drugs

Avg: 64%

$218
Average prescription price

Avg: $170

DOUGLAS KAHN D.O.

Pulmonary Disease

667

$130K

187
149 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

75%
prescriptions for brand name drugs

Avg: 64%

$195
Average prescription price

Avg: $170

JOSE MENDEZ M.D.

Pulmonary Disease

659

$208K

189
160 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

75%
prescriptions for brand name drugs

Avg: 64%

$315
Average prescription price

Avg: $170

DAVID OELBERG M.D.

Pulmonary Disease

657

$145K

175
149 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

81%
prescriptions for brand name drugs

Avg: 64%

$221
Average prescription price

Avg: $170

JEFFREY NASCIMENTO DO

Pulmonary Disease

651

$157K

138
102 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 64%

$241
Average prescription price

Avg: $170

JOHN URBANETTI MD

Pulmonary Disease

648

$101K

90
71 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

67%
prescriptions for brand name drugs

Avg: 64%

$156
Average prescription price

Avg: $170

MARK METERSKY MD

Pulmonary Disease

640

$96.3K

90
70 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 64%

$150
Average prescription price

Avg: $170

ERIC JIMENEZ M.D.

Pulmonary Disease

601

$138K

121
96 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

81%
prescriptions for brand name drugs

Avg: 64%

$230
Average prescription price

Avg: $170

NICOLE WEINREB M.D.

Pulmonary Disease

601

$115K

92
67 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 64%

$191
Average prescription price

Avg: $170

ABHIJITH HEGDE M.D.

Pulmonary Disease

574

$114K

178
147 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

67%
prescriptions for brand name drugs

Avg: 64%

$198
Average prescription price

Avg: $170

LYNN TANOUE MD

Pulmonary Disease

564

$110K

56
42 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 64%

$195
Average prescription price

Avg: $170

GEOFFREY CHUPP MD

Pulmonary Disease

558

$148K

58
31 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

77%
prescriptions for brand name drugs

Avg: 64%

$265
Average prescription price

Avg: $170

HERBERT KNIGHT MD

Pulmonary Disease

512

$89.3K

76
56 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

77%
prescriptions for brand name drugs

Avg: 64%

$174
Average prescription price

Avg: $170

NATALYA THOREVSKA M.D

Pulmonary Disease

487

$147K

129
99 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

66%
prescriptions for brand name drugs

Avg: 64%

$302
Average prescription price

Avg: $170

STEVEN THAU M.D.

Pulmonary Disease

474

$233K

79
67 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

76%
prescriptions for brand name drugs

Avg: 64%

$491
Average prescription price

Avg: $170

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank